BIOMARKER:

EGFR exon 18 mutation

Entrez ID:

Related biomarkers:

‹

›

EGFR exon 18 mutation EGFR exon 18 mutation	Non Small Cell Lung Cancer NSCLC	EGFR exon 18 mutation EGFR exon 18 mutation	Non Small Cell Lung Cancer NSCLC	afatinib Sensitive: C2 – Inclusion Criteria	afatinib Sensitive: C2 – Inclusion Criteria
EGFR exon 18 mutation EGFR exon 18 mutation	Non Small Cell Lung Cancer NSCLC	EGFR exon 18 mutation EGFR exon 18 mutation	Non Small Cell Lung Cancer NSCLC	erlotinib Sensitive: C2 – Inclusion Criteria	erlotinib Sensitive: C2 – Inclusion Criteria
EGFR exon 18 mutation EGFR exon 18 mutation	Non Small Cell Lung Cancer NSCLC	EGFR exon 18 mutation EGFR exon 18 mutation	Non Small Cell Lung Cancer NSCLC	bevacizumab + erlotinib Sensitive: C3 – Early Trials	bevacizumab + erlotinib Sensitive: C3 – Early Trials
EGFR exon 18 mutation EGFR exon 18 mutation	Non Small Cell Lung Cancer NSCLC	EGFR exon 18 mutation EGFR exon 18 mutation	Non Small Cell Lung Cancer NSCLC	neratinib Sensitive: C3 – Early Trials	neratinib Sensitive: C3 – Early Trials
EGFR exon 18 mutation EGFR exon 18 mutation	Non Small Cell Lung Cancer NSCLC	EGFR exon 18 mutation EGFR exon 18 mutation	Non Small Cell Lung Cancer NSCLC	EGFR inhibitor Sensitive: C3 – Early Trials	EGFR inhibitor Sensitive: C3 – Early Trials
EGFR exon 18 mutation EGFR exon 18 mutation	Non Small Cell Lung Cancer NSCLC	EGFR exon 18 mutation EGFR exon 18 mutation	Non Small Cell Lung Cancer NSCLC	FCN-411 Sensitive: C3 – Early Trials	FCN-411 Sensitive: C3 – Early Trials
EGFR exon 18 mutation EGFR exon 18 mutation	Lung Adenocarcinoma LUAD	EGFR exon 18 mutation EGFR exon 18 mutation	Lung Adenocarcinoma LUAD	bevacizumab + afatinib Sensitive: C4 – Case Studies	bevacizumab + afatinib Sensitive: C4 – Case Studies